文献速递痛风与晶体性关节病

超声检测的晶体沉积与临床发作在成功降尿酸治疗中消退:NOR-Gout 研究 5 年随访结果

Ultrasound-detected crystal depositions and clinical flares dissolve during successful urate-lowering therapy: 5-year follow-up results from the treat-to-target NOR-Gout study.
PubMed 文献 · Ann Rheum Dis · 2025-11-20

NOR-Gout 研究对近期痛风发作患者实施达标降尿酸治疗(T2T-ULT)并随访 5 年,209 例基线患者中 163 例完成 5 年检查。5 年时血尿酸从基线 500 μmol/L 降至 337 μmol/L(P < .001),71.2% 患者血尿酸 <360 μmol/L,所有超声晶体沉积均减少(P < .001),双轨征完全溶解率 83.4%、痛风石完全溶解率 63.2%,仅 16% 患者前一年有发作且这些患者血尿酸和晶体沉积更高(P = .035-.006)。

要点

  • 5 年达标降尿酸治疗使 71.2% 患者血尿酸 <360 μmol/L,血尿酸从基线 500 μmol/L 降至 337 μmol/L(P < .001)。
  • 5 年时所有超声晶体沉积均减少(P < .001),双轨征完全溶解率 83.4%,痛风石完全溶解率 63.2%。
  • 仅 16% 患者前一年有发作,这些患者血尿酸和晶体沉积更高(P = .035-.006)。

核心结论

  • 5 年达标降尿酸治疗使多数患者达到血尿酸目标、晶体沉积减少,且多数患者双轨征和痛风石溶解。
  • 仅少数患者经历发作,这些患者血尿酸和晶体沉积水平更高,支持维持血尿酸低水平的重要性。

研究设计与样本

  • 本研究为 5 年随访研究,纳入近期痛风发作患者并启动达标降尿酸治疗(T2T-ULT),第 1 年门诊随访、第 2-5 年由全科医生随访,访视点为基线、1 年、2 年和 5 年。
  • 基线纳入 209 例患者(平均年龄 56.4 岁,病程 7.9 年),5 年时 163 例患者接受检查。
  • 每次访视评估血尿酸、双侧手、肘、膝、踝、足超声晶体沉积(双轨征、痛风石和聚集物)及前一年发作次数;计算包括独立或配对样本 t 检验、方差分析(ANOVA)和线性回归分析。

主要发现

  • 5 年访视时血尿酸从基线 500 μmol/L 降至 337 μmol/L(P < .001),71.2% 患者血尿酸 <360 μmol/L。
  • 5 年时所有超声晶体沉积均减少(P < .001),双轨征完全溶解率 83.4%,痛风石完全溶解率 63.2%(仅检查第一跖趾关节即可识别其中多数患者)。
  • 仅 16% 患者前一年有发作,这些患者血尿酸和晶体沉积更高(P = .035-.006)。

临床怎么用

  • 对近期痛风发作患者启动达标降尿酸治疗并长期随访,5 年时多数患者可达血尿酸目标并出现晶体沉积减少或溶解。
  • 5 年时仍有发作的患者血尿酸和晶体沉积更高,原文支持维持血尿酸低水平的重要性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aims of this 5-year study were to explore the maintenance of low serum uric acid (sUA) during treat-to-target urate-lowering therapy (T2T-ULT) and whether long-term low sUA results in continuous decrease of ultrasound-detected crystal depositions, complete dissolution of depositions, and reduction of flares. METHODS: Patients with a recent gout flare were included, initiated T2T-ULT, and were followed for 5 years (outpatient clinic year 1, general practitioner years 2-5) with visits at baseline, 1, 2, and 5 years. Each visit included assessment of sUA, ultrasound examination for crystal depositions (double contour, tophi, and aggregates) in bilateral hands, elbows, knees, ankles, feet, and number of flares the previous year. Calculations included independent or paired samples t-tests, analysis of variance (ANOVA), and linear regression analyses. RESULTS: Of the 209 patients included at baseline (mean age 56.4 years, disease duration 7.9 years), 163 patients were examined at 5 years. At the 5-year visit, sUA was reduced from 500 (baseline) to 337 μmol/L (P < .001), 71.2% had sUA <360 μmol/L, all ultrasound depositions were reduced (P < .001), full dissolution of double contour (83.4%) and tophi (63.2%) (where examining only first metatarsophalangeal joints identified most of these patients), and only 16% had flares the previous year all of whom had higher sUA and depositions (P = .035-.006). CONCLUSIONS: Five years of T2T-ULT resulted in most patients achieving sUA target, reduction of crystal depositions, and dissolution of double contour and tophi in most patients. Only a few patients experienced flares, and they had higher levels of sUA and crystal depositions, supporting the importance of keeping sUA low.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Hammer HB, Karoliussen L, Terslev L, et al. Ultrasound-detected crystal depositions and clinical flares dissolve during successful urate-lowering therapy: 5-year follow-up results from the treat-to-target NOR-Gout study. Ann Rheum Dis. 2025. PMID: 41271521. doi:10.1016/j.ard.2025.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。